Anovulation

• EMA approval · 2026-03-25
  EMA Authorised: Bemfola (follitropin alfa) — Gedeon Richter Plc.

  The EMA authorised Bemfola (follitropin alfa) with Gedeon Richter Plc. as the marketing authorization holder. The therapeutic area listed is…

• EMA approval · 2025-05-27
  EMA Authorised: Ovaleap (follitropin alfa) — Theramex Ireland Limited

  EMA authorised Ovaleap (follitropin alfa) for the treatment of anovulation. The marketing authorisation holder is Theramex Ireland Limited.

• EMA approval · 2025-05-23
  EMA Authorised: Ovitrelle (choriogonadotropin alfa) — Merck Europe B.V.

  The EMA authorised Ovitrelle (choriogonadotropin alfa) for triggering ovulation in women undergoing assisted reproductive techniques for inf…

• EMA approval · 2025-01-09
  EMA Authorised: GONAL-f (follitropin alfa) — Merck Europe B.V.

  The European Medicines Agency authorised GONAL-f (follitropin alfa) by Merck Europe B.V. for indications including Anovulation, infertility,…

• FDA approval · 2024-02-07
  FDA Approved: FOLLISTIM AQ — Supplemental Application (Organon LLC)

  FDA approved a supplemental application for FOLLISTIM AQ (FOLLITROPIN) from Organon LLC. The action updates the regulatory status for the pr…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2023-10-04
  EMA Authorised: Rekovelle (follitropin delta) — Ferring Pharmaceuticals A/S

  EMA authorised Rekovelle (follitropin delta) for the treatment of anovulation.